# Why Benjamin Graham Might Have Picked Edwards Lifesciences (EW)

Edwards Lifesciences is currently trading at \$90.99 per share and has a Graham number of \$23.76, which implies that it is 283.0% above its fair value. We calculate the Graham number as follows:

√(22.5 * 5 year average earnings per share * book value per share) = √(22.5 * 1.86 * 11.816) = 23.76

The Graham number is one of seven factors that Graham enumerates in Chapter 14 of The Intelligent Investor for determining whether a stock offers a margin of safety. Rather than use the Graham number by itself, its best to consider it alongside the following fundamental metrics:

Sales Revenue Should Be No Less Than \$500 million

For Edwards Lifesciences, average sales revenue over the last 5 years has been \$8.06 Billion, so in the context of the Graham analysis the stock has impressive sales revenue. Originally the threshold was \$100 million, but since the book was published in the 1970s it's necessary to adjust the figure for inflation.

Current Assets Should Be at Least Twice Current Liabilities

We calculate Edwards Lifesciences's current ratio by dividing its total current assets of \$4.04 Billion by its total current liabilities of \$1.2 Billion. Current assets refer to company assets that can be transferred into cash within one year, such as accounts receivable, inventory, and liquid financial instruments. Current liabilities, on the other hand, refer to those that will come due within one year. In Edwards Lifesciences’s case, current assets outweigh current liabilities by a factor of 3.4.

The Company’s Long-term Debt Should Not Exceed its Net Current Assets

This means that its ratio of debt to net current assets should be 1 or less. Since Edwards Lifesciences’s debt ratio is 0.4, the company has healthy debt levels with a debt to net current asset of 0.4. We calculate Edwards Lifesciences’s debt to net current assets ratio by dividing its total long term of debt of \$597.0 Million by its current assets minus total liabilities of \$2.64 Billion.

The Stock Should Have a Positive Level of Retained Earnings Over Several Years

Edwards Lifesciences had good record of retained earnings with an average of \$3.52 Billion. Retained earnings are the sum of the current and previous reporting periods' net asset amounts, minus all dividend payments. It's a similar metric to free cash flow, with the difference that retained earnings are accounted for on an accrual basis.

There Should Be a Record of Uninterrupted Dividend Payments Over the Last 20 Years

We have no record of Edwards Lifesciences offering a regular dividend within the last twenty years.

A Minimum Increase of at Least One-third in Earnings per Share (EPS) Over the Past 10 Years

To determine Edwards Lifesciences's EPS growth over time, we will average out its EPS for 2008, 2009, and 2010, which were \$1.10, \$1.95, and \$0.54 respectively. This gives us an average of \$1.20 for the period of 2008 to 2010. Next, we compare this value with the average EPS reported in 2021, 2022, and 2023, which were \$2.38, \$2.44, and \$2.30, for an average of \$2.37. Now we see that Edwards Lifesciences's EPS growth was 97.5% during this period, which satisfies Ben Graham's requirement.

Based on the above analysis, we can conclude that Edwards Lifesciences meets most of Benjamin Graham's criteria for an undervalued stock because it is trading above its fair value and has:

• impressive sales revenue
• an excellent current ratio of 3.38
• healthy debt levels with a debt to net current asset of 0.4
• good record of retained earnings
• no dividend record from EDGAR
• a strong EPS growth trend
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.